LIFECYCLE PHARMA A/S PASSING OF ANNUAL GENERAL MEETING - SUBSEQUENT CONSTITUTION OF THE BOARD OF DIRECTORS.

Company Announcement no. 11/2009

To: NASDAQ OMX Copenhagen           Hørsholm, Denmark, April 23, 2009			 

LIFECYCLE PHARMA A/S PASSING OF ANNUAL GENERAL MEETING - SUBSEQUENT
CONSTITUTION OF THE BOARD OF DIRECTORS. 


Summary: At LifeCycle Pharma A/S' Annual General Meeting held earlier today,
the annual report was approved and discharge was given to the Board of
Directors and the Management. All proposals from the Board of Directors were
adopted. 


LifeCycle Pharma A/S (OMX: LCP) (the “Company”) held its Annual General Meeting
today Thursday, April 23, 2009 at LifeCycle Pharma A/S, Kogle Allé  4, 2970
Hørsholm, Denmark. 

At the meeting, the Claus Bræstrup, Chairman of the Board, and President and
CEO, Dr. Jim New gave a report on the Company's activities during the year and
presented the audited Annual Report. The audited Annual Report was approved and
discharge was given to the Board of Directors and the Management. 

It was decided that the year's net loss of DKK 149.8 million be carried forward
by transfer to accumulated deficit. The fee to the Board of Directors for 2008
was approved as a separate item on the agenda. 

All existing members of the Board of Directors were re-elected - except Claus
Bræstrup, who did not seek re-election - all for a period of one year that
expires at the Annual General Meeting to be held in 2010. 

PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab, was re-elected
as the Company's elected auditor. 

The proposals from Board of Directors to change the articles of association
were approved as follows: 

•	Change of Article 8 to authorize the Board of Directors until April 22, 2014
to issue additional warrants - without pre-emption rights for the existing
shareholders - that give the right to subscribe up to a total of nominally DKK
2,500,000 shares in the Company to employees, executive directors, board
members, consultants and advisors to the Company and its subsidiaries and to
implement the corresponding capital increases. 

•	 Changed the Company´s Share Register to be kept by I-nvestor Danmark A/S.

•	Added “Approval of Fee to the Board of Directors” as a new item on the agenda
of the Annual General Meeting. 

The Board of Directors was authorized by the General Meeting, until the next
Annual General Meeting to arrange for the Company to acquire own shares up to a
total nominal value of 10% of the Company's nominal share capital. The purchase
price of such shares may not differ by more than 10% from the price quoted on
NASDAQ OMX Copenhagen at the time of the purchase. 

The chairman of the Annual General Meeting, with right of substitution, was
authorized to register the resolutions passed by the general meeting to the
Danish Commerce and Companies Agency and to make such alterations to as the
Agency may require or request for registration or approval. 

Subsequent Constitution of the Board of Directors

After the Annual General Meeting, the Board of Directors convened and
constituted itself with Dr.Paul Edick as Chairman of the Board of Directors as
well as Chairman of the Compensation Committee and with Kurt Anker Nielsen as
Chairman of the Audit Committee. 


For more information, please contact: 

LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: PSK@lcpharma.com




About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide™, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP). 

For further information, please visit www.lcpharma.com.